Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers Journal Article


Authors: Archey, W. B.; McEachern, K. A.; Robson, M.; Offit, K.; Vaziri, S. A. J.; Casey, G.; Borg, A.; Arrick, B. A.
Article Title: Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers
Abstract: A distinctive feature of BRCA1-linked breast cancers is that they typically do not express estrogen receptor-alpha (ERalpha). Previous investigation suggests that methylation of CpGs within the ERa promoter mediates repression of gene expression in some ERalpha-negative breast cancers. To determine if methylation of CpGs within the ERalpha promoter is associated with BRCA1-linked breast cancers, we evaluated methylation in exon 1 of the ERalpha gene in 40 ERalpha-negative breast cancers, 20 of which were non BRCA1-linked and 20 BRCA1-linked. CpG methylation was evaluated by either methylation-sensitive restriction digest (HpaII), methylation-sensitive PCR (MSP), or direct sequencing of bisulfite-treated genomic DNA. Results from HpaII digests and MSP documented a high degree of methylation, the MSP data showing slightly higher methylation in the BRCA1-linked group. CpGs analysed by direct sequencing showed an overall average methylation of 25% among non BRCA1-linked cancers and 40% among BRCA1-linked cancers (P=0.0031). The most notable difference was found at five particular CpGs, each of which exhibited a greater than twofold increase in methylation in the BRCA1-linked group compared to the non BRCA1-linked group (P < 0.03 for each CpG). Methylation of certain critical CpGs may represent an important factor in transcriptional repression of the ERa gene in BRCA1-linked breast cancers.
Keywords: methylation; breast cancer; dna; tumors; estrogen receptor; transcriptional activation; brca1; mutations; expression; ovarian-cancer; promoter; carcinomas; sporadic breast
Journal Title: Oncogene
Volume: 21
Issue: 46
ISSN: 0950-9232
Publisher: Nature Publishing Group  
Date Published: 2002-10-10
Start Page: 7034
End Page: 7041
Language: English
ACCESSION: WOS:000178424900006
DOI: 10.1038/sj.onc.1205844
PROVIDER: wos
PUBMED: 12370825
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Kenneth Offit
    788 Offit
  2. Mark E Robson
    676 Robson